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Medulloblastoma is the most common malignant brain 
tumor in children. The presence of microsatellite insta-
bility (MSI) in brain tumors, particularly medulloblas-
tomas, has not been properly addressed. The aim of the 
present study was to evaluate the role of MSI in medullo-
blastoma carcinogenesis. MSI status was determined in 
36 patients using a pentaplex PCR of quasimonomorphic 
markers (NR27, NR21, NR24, BAT25, and BAT26). 
Methylation status of mismatch repair (MMR) genes 
was achieved by methylation-specific multiplex ligation-
dependent probe amplification (MLPA). In addition, 
MutS homolog 6 (MSH6) expression was determined 
by immunohistochemistry. Mutations of 10 MSI target 
genes (TCF4, XRCC2, MBD4, MRE11, ATR, MSH3, 
TGFBR2, RAD50, MSH6, and BAX) were studied by 
pentaplex PCR followed by analysis with GeneScan 
3.7 software. Mutation analysis of hotspot regions of 
b-catenin (CTNNB1) and BRAF (v-raf murine sarcoma 
viral oncogene homolog B1) oncogenes was performed 
by PCR single-strand conformation polymorphism 
analysis followed by direct sequencing. Among the 36 
tumors, we found four (11%) cases with instability, 
one with high MSI and three with low MSI. Methyla-
tion analysis of MMR genes in cases presenting shifts 
on the MSI markers revealed mild hypermethylation of 
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MSH6 in 75% of cases, yet MSH6 was expressed in all 
the tumors. The MSI target genes MBD4 (methyl-CpG 
binding domain protein 4) and MRE11 (meiotic recom-
bination 11 homolog A) were mutated in two different 
tumors. No CTNNB1 or BRAF mutations were found. 
This study is the most comprehensive analysis of MSI 
in medulloblastomas to date. We observed the presence 
of MSI together with mutations of MSI target genes in 
a small fraction of cases, suggesting a new genetic path-
way for a role in medulloblastoma development. Neuro-
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Brain tumors are the second most common malig-nancy among children and the leading cause of cancer-related death in pediatric patients. The 
overall incidence rate for pediatric brain tumors (occur-
ring from birth through 19 years) is 4.3 per 100,000 
person-years.1 Among the different histological entities, 
medulloblastoma is the most common childhood malig-
nant brain tumor, accounting for approximately 20% of 
all pediatric intracranial tumors, with a peak incidence 
between 3 and 4 years of age.1 Medulloblastomas are 
less common in adults, with a peak incidence between 
20 and 35 years.2 Current therapy for this malignancy 
is very aggressive, including maximum surgical resec-
tion, craniospinal radiotherapy, and adjuvant chemo-
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therapy, yet the medulloblastoma 5-year survival rate 
is only 50%–60%,3,4 and these aggressive procedures 
frequently have serious neurocognitive and endocrine 
sequelae in survivors, particularly in younger patients.5
Genetic instability is a paramount feature of can-
cer, which leads to accumulation of genetic alterations 
that varies from subtle changes in DNA sequence to 
chromosomal abnormalities.6 Microsatellite instability 
(MSI) is a particular type of genetic instability affect-
ing short sequences of DNA repeats (microsatellites) 
found throughout the genome.6 MSI was first described 
in hereditary nonpolyposis colorectal cancer (HNPCC) 
and is present in the majority of these patients; currently, 
MSI analysis of this malignancy is standardized by the 
Bethesda guidelines.7 In colorectal cancer (CRC), the 
MSI phenotype appears to be related to particular clini-
cal and histopathological features, including location in 
the proximal colon, tumors poorly differentiated with 
mucinous and signet ring cells, high tumor lymphocyte 
infiltration, low frequency of distant metastasis, and a 
comparably good prognosis.8 The MSI phenotype is a 
consequence of deficient DNA mismatch repair (MMR), 
which fails to recognize errors introduced in microsatel-
lite regions during DNA replication. The loss of function 
of MMR family genes (MLH1, MLH3, MSH2, MSH3, 
MSH6, PMS1, and PMS2) is caused by germline muta-
tions in hereditary malignancies, whereas in sporadic 
cancers, MLH1 (mutL homolog 1, colon cancer, non-
polyposis type 2) promoter methylation has been shown 
to be the main cause of gene silencing.9 As naturally 
occurring replication errors are not efficiently repaired, 
tumors with MMR deficiencies have a higher number of 
nucleotide insertions/deletions in genes harboring mic-
rosatellites.6,9 The accumulation of activating or inac-
tivating frameshift mutations in genes that regulate cell 
functioning, such as TGFBR2 (transforming growth 
factor b type II receptor) and BAX (BCL2-associated 
X protein), is thought to be responsible for the tumori-
genic process of MSI in MMR-deficient cells.9 Particu-
larly important to oncological research is the evidence 
that many of these mutated genes, already identified in 
different tumors, also appear to have a role in the thera-
peutic response of different anticancer drugs.10–12
Previous studies have evaluated the presence of MSI 
in brain tumors, mainly gliomas. An absence or a rare 
incidence of MSI in adults and contradictory results in 
pediatric patients have been reported.13–21 In medullo-
blastoma, MSI status has not been properly character-
ized.
The aim of the present study was to evaluate the pres-
ence of MSI in medulloblastomas, using a panel of mark-
ers recommended by the revised Bethesda guidelines.7 
In addition, in tumors presenting MSI, we assessed the 
molecular status of MMR genes and the mutation pro-
files of 10 potential MSI target genes (TCF4, XRCC2, 
MBD4, MRE11, ATR, MSH3, TGFBR2, RAD50, 
MSH6, and BAX). Furthermore, we analyzed mutations 
of BRAF (v-raf murine sarcoma viral oncogene homolog 
B1) and b-catenin (CTNNB1).
Material and Methods
Patients and Tumor Samples
Formalin-fixed, paraffin-embedded samples from 36 
cases of medulloblastoma were retrieved from the 
Pathology Department of Santa Maria Hospital, Lisbon, 
Portugal. Tumor samples were classified according to 
WHO criteria.22 Thirty-four of the 36 cases were classic 
medulloblastomas, and the remaining two were classi-
fied as desmoplastic medulloblastomas. Of the patients, 
22 (61.1%) were male and 14 (38.9%) were female; the 
mean age was 19.5 years (range, 1.5–70 years; Table 1).
DNA Extraction
DNA was extracted from 10-μm-thick formalin-
fixed, paraffin-embedded tumor samples as previously 
described.23 Briefly, tissues were deparaffinized by a serial 
extraction with xylene and ethanol (100%/70%/50%), 
and separately selected areas of tumor and normal tis-
sue, when available, were microdissected using a ster-
ile needle and carefully collected into a 0.2-mL PCR 
tube. DNA was extracted using QIAamp DNA Micro 
Kit (Qiagen, Hilden, Germany), following the manufac-
turer’s instructions.
MSI Analysis
The MSI evaluation was performed using a multiplex 
PCR comprising five quasimonomorphic mononucle-
otide repeat markers (NR27, NR21, NR24, BAT25, and 
BAT26).24 Primer sequences were described previously.24 
Each antisense primer was end-labeled with 6-carboxy-
fluorescein (FAM), hexachloro-6-carboxyfluorescein 
(HEX), or tetrachloro-6-carboxyfluorescein (TET) fluo-
rescent marker. PCR was performed using the Qiagen 
Multiplex PCR Kit, and then products were separated 
using an ABI Prism 310 single capillary genetic analyzer 
(Applied Biosystems, Foster City, CA, USA). The MSI 
status of the tumor was analyzed using GeneScan analy-
sis software (version 3.7; Applied Biosystems). Cases 
exhibiting instability at two or more markers were con-
sidered to have high MSI (MSI-H), those with instability 
at one marker were defined as having low MSI (MSI-L), 
and those showing no instability were defined as micro-
satellite stable (MSS), as previously described.25 DNA 
from the cell lines HCT15 (MSI) and DAOY (MSS) 
were used as positive and negative controls, respectively. 
The quasimonomorphic variation range of each marker 
(described by Buhard et al.26) was established in our 
analysis using a series of DNA from six healthy people.
Mutation Analysis of MSI Target Genes
Selected genes containing repeated sequences previously 
described as frequent targets for instability were chosen 
for frameshift mutation study by fragment analysis and 
further genomic sequencing confirmation. The selected 
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ABI Prism 310 single capillary genetic analyzer (Applied 
Biosystems), and the PCR products profiles were ana-
lyzed using GeneScan 3.7 software (Applied Biosys-
tems). Several normal DNA samples were used to estab-
lish profile patterns for each gene, and mutation analysis 
was performed comparing the peak pattern alterations 
with the reference peak size and pattern.27,28 Analyses 
of samples presenting abnormal profiles were repeated 
three times by multiplex and monoplex PCR. In addi-
tion, PCR followed by direct sequencing was performed 
to confirm the presence of a frameshift mutation.
genes were transcription factor-4 (TCF4; poly[A]9), 
X-ray repair cross-complementing protein 2 (XRCC2; 
T8), methyl-CpG binding domain protein 4 (MBD4; 
A10), meiotic recombination 11 homolog A (MRE11; 
T11), ataxia telangiectasia and Rad3 related check-
point kinase 1 (ATR; A10), MSH3 (A8), TGFBR2 
(A10), RAD50 homolog (RAD50; A9), MSH6 (C8), and 
BAX (G8).27,28 PCR was performed with primers, end-
labeled with FAM, HEX, or TET fluorescent markers, 
specific for each selected candidate gene, as previously 
described.27,28 PCR products were separated using an 
Table 1. Detection of microsatellite instability (MSI) in medulloblastomas using five mononucleotide repeat markers
  
Histological 
                 MSI Detection
Case Gender/Age (Years) Type NR27 NR21 NR24 BAT25 BAT26 MSI State
M1 M/11 Classic 86 106 123 148 179 MSS
M2 F/16 Classic 86 107 123 148 180 MSS
M3 M/35 Classic 87 107 122 148 180 MSS
M4 M/33 Classic 86 107 123 148 180 MSS
M5 M/1.5 Classic 86 102–107 122 148 179 MSS
M6 M/10 Classic 86 107 123 147 180 MSS
M7 F/70 Classic 86 102–106 123 147 180 MSS
M8 M/20 Classic 87 106 122 148 180 MSS
M9 F/26 Classic 86 102–107 123 147 180 MSS
M10 F/10 Classic 86 106 123 147 180 MSS
M11 F/1.5 Classic 87 106 123 148 180 MSS
M12 F/1.5 Classic 87 106 123 148 180 MSS
M13 M/21 Desmoplastic 84 105 122 146 168 MSI-H
M14 M/11 Classic 86 107 122 148 179 MSS
M15 M/28 Classic 87 107 123 146 179 MSS
M16 M/34 Classic 86 107 122 148 179 MSS
M17 M/6 Classic 86 106 123 148 180 MSS
M18 F/24 Classic 86 106 122 147 180 MSS
M19 F/34 Classic 87 106 123 148 179 MSS
M20 M/12 Classic 86 106 123 147 180 MSS
M21 M/10 Classic 86 105 122 147–150 179 MSI-L
M22 F/16 Classic 86 106 123 148 180 MSS
M23 M/8 Classic 86 107 123 148 NA MSS
M24 M/7 Classic 87 106 123 148 180 MSS
M25 M/35 Classic 87 107 123 144–148 179 MSI-L
M26 M/2 Classic 86 106 123 147 180 MSS
M27 M/65 Classic 86 107 122 148 180 MSS
M28 M/39 Classic 86 107 123 147 180 MSS
M29 F/8 Classic 87 107 122 147 179 MSS
M30 F/26 Classic 86 106 122 148 179 MSS
M31 F/2 Classic 86 107 122 146 180 MSS
M32 M/33 Classic 86 106 122 147 180 MSS
M33 M/4 Classic 86 107 123 148 180 MSS
M34 F/9 Classic 86 107 123 147 180 MSS
M35 M/13 Classic 84 106 122 146 179 MSI-L
M36 F/18 Desmoplastic 86 106 123 148 180 MSS
Abbreviations: M, male; MSS, microsatellite stability; F, female; MSI-H, high microsatellite instability; MSI-L, low microsatellite instability; NA, not amplified. Boldface indicates 
MSI markers presenting alterations.
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Mutation Analysis of CTNNB1 and BRAF Oncogenes
Screening of hotspot mutations on CTNNB1 exon 3 and 
BRAF exon 15 was carried out by PCR single-strand con-
formation polymorphism as previously described.29–31
Methylation Analysis of the MMR System Genes
The study of MLH1, MLH3, MSH2, MSH3, MSH6, 
and PMS2 (PMS1 postmeiotic segregation increased 2) 
MMR gene methylation was performed by methylation-
specific MLPA kit ME011 according to the manufac-
turer’s instructions (MRC-Holland, Amsterdam, The 
Netherlands).32 Briefly, 100 ng tumoral DNA was dena-
turated in 5 μl ultrapure water at 98°C for 5 min and 
then incubated with the probe mix for 20 h at 60°C. 
After probe hybridization, each sample was divided 
into two tubes. Half of the sample was ligated using a 
ligase enzyme, and in the other half ligation was com-
bined with HhaI digestion, resulting in ligation of the 
methylated sequences only. The resulting products were 
amplified by PCR using a FAM-labeled primer follow-
ing manufacturer’s instructions. PCR products were 
analyzed on an ABI Prism 310 single capillary genetic 
analyzer (Applied Biosystems) using GeneScan 3.7 soft-
ware (Applied Biosystems). Duplicate experiments were 
performed for methylation analysis, and average ratios 
were calculated. Additionally, the overall average of 
the different probes of the same gene was calculated. 
Data analysis was performed as described by the manu-
facturer. We interpreted (average) ratios as absence of 
hypermethylation (0.00–0.24), mild hypermethylation 
(0.25–0.49), moderate hypermethylation (0.50–0.74), 
and extensive hypermethylation (>0.75), as previously 
described.33
Immunohistochemistry to the MSH6 MMR  
System Protein
Immunohistochemistry analysis of MSH6 protein was 
performed using 3-μm paraffin-embedded tissue sec-
tions. Tissue sections were deparaffined, rehydrated 
in graded ethanol, and washed. Antigen retrieval was 
achieved by microwave treatment in 1 mM EDTA (pH 
8.0) for 15 min. Endogenous peroxidase activity was 
blocked by incubation with 3% H2O2. To block non-
specific protein binding, sections were incubated with 
R.T.U. normal horse serum (R.T.U. vectastain Elite 
ABC kit; Vector Laboratories, Burlingame, CA, USA). 
A primary antibody to MSH6 (clone 44, purified mouse 
anti-MSH6; BD Transduction Laboratories, BD Biosci-
ences, Erembodegem, Belgium) was applied at a concen-
tration of 1:100 and incubated overnight at room tem-
perature. Antigen–antibody complexes were revealed 
by a 10-min incubation with R.T.U. biotinylated uni-
versal antibody antirabbit/mouse IgG (H 1 L) (R.T.U. 
vectastain Elite ABC kit; Vector Laboratories) followed 
by incubation with R.T.U. vectastain Elite ABC reagent 
(R.T.U. vectastain Elite ABC kit; Vector Laboratories) 
for 10 min 3,3/-Diaminobenzidine (Dako Liquid DAB, 
DakoCytomation, VitaReal, Carpinteria, CA, USA) was 
used as a chromogen. Slides were counterstained with 
hematoxylin. Normal colon tissue was used as a positive 
control. A negative control was also used (DakoCytoma-




MSI analysis was performed for 36 tumors using a penta-
plex PCR of quasimonomorphic markers recommended 
by the revised Bethesda guidelines.7 Among all samples, 
we found four (11.1%) cases with instability—one with 
MSI-H and three with MSI-L—and 32 MSS (88.9%) 
(Table 1, Fig. 1). Regarding adult and pediatric patients, 
we found 13% (2 of 15) MSI tumors (M13, M25) in the 
adult set, one of which was MSI-H (M13). In pediatric 
samples, two cases (9.5%) were MSI-L (M21, M35). Case 
M13 presented mutations in NR27 and BAT26 markers, 
cases M21 and M25 presented alterations in BAT25, and 
M35 presented alterations in NR27. Three cases (M5, 
M7, and M9) presented allele variants in NR21. Case 
M13 had adjacent normal DNA available, which did not 
exhibit the alterations present in the tumor DNA (Fig. 1). 
In addition, the MSI status of both tumor and normal 
DNA was confirmed by direct sequencing.
MMR Gene Methylation
Promoter abnormal methylation of MMR genes is the 
main mechanism underlying MSI phenotype in sporadic 
tumors. Therefore, we analyzed methylation of the main 
Fig. 1. Altered markers in the microsatellite instability cases: pen-
taplex PCR with the microsatellite quasimonomorphic markers 
(NR27, NR21, NR24, BAt25, and BAt26). Case M13 presented 
mutation in NR27 and BAt26 microsatellite markers, cases M21 
and M25 were mutated in the BAt25 marker, and M35 in NR27 
(altered markers indicated with arrows).
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MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, 
and PMS2) in the MSI-H tumor (M13), in three tumors 
presenting MSI-L (M21, M25, and M35), and in the 
three additional cases presenting an allele variant in the 
NR21 marker (Table 2). Except for MSH6, none of the 
other MMR genes showed promoter gene hypermethy-
lation. MSH6 presented mild hypermethylation in 43% 
(three of seven) of the cases analyzed: in two MSI (M13 
and M21) and one MSS (M9).
Immunohistochemistry of the MSH6 MMR  
System Protein
The immunohistochemical assay was performed to 
complement the methylation study of MSH6 and to 
understand the effects of mild gene hypermethylation 
on protein expression levels. All cases exhibited MSH6 
positivity, but cases M5 and M25 showed weaker stain-
ing (Fig. 2).
Mutation Analysis of MSI Target Genes
Selected MSI target genes (TCF4, XRCC2, MBD4, 
MRE11, ATR, MSH3, TGFBR2, RAD50, MSH6, and 
BAX) were analyzed for frameshift mutations in the MSI 
tumors and in the cases presenting an allele variant in 
the NR21 marker (Table 3). Among the genes studied, 
MBD4 and MRE11 have been shown to be mutated in 
one MSI sample each (1 of 4 5 25%) in M13 (MSI-H) and 
M21 (MSI-L). Both MBD4 and MRE11 had a hetero-
zygous insertion of one base pair. Therefore, two of the 
four tumors with instability presented mutation in one 
MSI target gene. The presence of frameshift mutations 
was confirmed by direct sequencing and demonstrated 
to be heterozygous by both techniques (Figs. 3 and 4).
Mutation Analysis of CTNNB1 and BRAF Oncogenes
Because the Wingless/Wnt signal transduction path-
way is involved in medulloblastoma development, we 
searched for mutations in its critical downstream effec-
tor CTNNB1. All cases were analyzed for mutations 
in exon 3. No medulloblastoma showed any CTNNB1 
genetic alteration.
BRAF mutations, particularly the V600E hotspot 
mutation, have been described to be involved in co-
lorectal carcinomas exhibiting MSI. None of the MSI 
medulloblastomas exhibited BRAF exon 15 mutations.
Discussion
MSI was first identified in and is present in about 
90% of HNPCC cases.34 This phenotype has also 
been described in many sporadic human malignancies 
and is present in approximately 10%–15% of colorec-
tal, endometrial, and gastric cancers.34 The few stud-
ies reporting MSI status in brain tumors showed that 
this phenotype is a rare event (0%–8%) in adult spo-
radic CNS tumors.13–17,19 Regarding pediatric data, the 
results are contradictory: MSI was found in 0%–27% 
of CNS tumors studied.13–16,18–21 In the present study, 
we screened 21 pediatric and 15 adult medulloblastomas 
for MSI. The overall incidence of instability was 11% 
(4 of 36 cases), with three cases showing MSI-L and a 
single case with MSI-H, from two adults and two pedi-
atric patients. According to these results, the presence of 
MSI in medulloblastomas appears not to be age-related, 
in contrast to data from other CNS tumors. The few 
studies that analyzed MSI status in medulloblastomas 
reported the absence of genetic instability.15,21,35 How-
ever, these studies evaluated a very small number of 
cases, some not differentiating medulloblastomas from 
other primitive neuroectodermal tumors,15,21 using pan-
els of microsatellite markers that were limited for MSI 
status assessment.16,17,21 In this work, we used a gold 
standard panel of microsatellite markers recommended 
by the revised Bethesda guidelines for CRC.7 This panel 
of mononucleotide markers provides high specificity and 
sensitivity for MSI detection, and their quasimonomor-
phic nature allows the analysis of MSI status without the 
need to evaluate corresponding normal tissue.24
The main mechanism driving MSI in sporadic tumors 
has been shown to be methylation of MMR genes. We 
analyzed the methylation of the MLH1, MLH3, MSH2, 
MSH3, MSH6, and PMS2 MMR genes in tumors with 
MSI and in those presenting an allelic variant of the 
NR21 marker but considered MSS, and found mild 
Table 2. Methylation status of mismatch repair (MMR) genes in medulloblastomas
 MMR Gene Methylation (Average) 
Case MSI Status MLH1 MLH3 MSH2 MSH3 MSH6 PMS2
M5 MSS U (0.15) U (0.05) U (0.08) U (0.17) U (0.19) U (0.10)
M7 MSS U (0.05) U (0.02) U (0.07) U (0.19) U (0.16) U (0.11)
M9 MSS U (0.11) U (0.00) U (0.05) U (0.17) M (0.27) U (0.09)
M13 MSI U (0.15) U (0.06) U (0.11) U (0.20) M (0.29) U (0.13)
M21 MSI U (0.11) U (0.18) U (0.06)  U (0.23) M (0.26) U (0.11)
M25 MSI U (0.10) U (0.00) U (0.05) U (0.15) U (0.23) U (0.07)
M35 MSI U (0.02) U (0.08) U (0.08) U (0.00) U (0.12) U (0.07)
Abbreviations: MSI, microsatellite instability; MLH1 and MLH3, mutL homolog 1, colon cancer, nonpolyposis, types 2 and 3; MSH2, MSH3, and 
MSH6, MutS homologs 2, 3, and 6; PMS2, PMS1 postmeiotic segregation increased 2; MSS, microsatellite stability; U, unmethylated; M, methylated. 
Boldface indicates the presence of gene methylation.
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hypermethylation levels of the MSH6 gene in two cases 
of MSI (M13 and M21) and one case of MSS (M9). Nev-
ertheless, the presence of mild hypermethylation was not 
transduced in a lack of protein expression and might 
not be the cause of the MSI phenotype. It remains to 
be determined in MSI-positive medulloblastomas which 
MMR protein is affected and by which mechanism. The 
presence of MMR deficiencies is well correlated with the 
Fig. 2. Representative histology and immunohistochemistry results: hematoxylin and eosin (A, C, e, and G) and MutS homolog 6 (MSH6) 
immunohistochemistry (B, D, F, and H) for the microsatellite-instability–positive medulloblastomas M13 (A and B), M21 (C and D), M25 
(e and F), and M35 (G and H). original magnification: 3100.
MSI status in several tumors, such as CRC,36 ovarian 
carcinoma,37,38 and endometrial carcinoma,38,39 where 
MSI-H tumors present inactivation of MMR proteins 
whereas the genes leading to MSI-L are unclear.7,40 
However, in other tumor entities such as Ewing tumors, 
such associations were not reported.41 This suggests 
that MMR protein deficiencies in MSI-positive tumors 
depend not only on MSI levels but also on the tumor 
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type. Data on MMR gene alterations are scarce in CNS 
tumors. In medulloblastoma, only one study has exam-
ined MMR protein expression.42 The authors reported 
the absence of any deficiency in MLH1, MSH2, and 
PMS2 proteins in a series of 22 medulloblastomas.42
In order to evaluate the mutagenic effect of the MSI 
phenotype in medulloblastomas, we performed a muta-
tion analysis of candidate MSI target genes. We studied 
10 candidate genes—TCF4, XRCC2, MBD4, MRE11, 
ATR, MSH3, TGFBR2, RAD50, MSH6, and BAX—
previously described to be frequently mutated in MSI 
tumors such as colorectal, urothelial, or endometrium 
cancers.27,28,43 Most of the candidate target gene muta-
tions were primarily found and mainly analyzed in 
MSI-H CRC. Although several of these mutations have 
already been reported in different MSI-H tumors, this is 
not true for all different MSI cancers. We found altera-
tions in MBD4 and MRE11 genes in two of the four MSI 
Table 3. Candidate microsatellite instability target gene frameshift mutations detected in medulloblastomas 
 TCF4 XRCC2 MBD4 MRE11 ATR MSH3 TGFBR2 RAD50 MSH6 BAX Mutation 
Case (A9) (T8) (A10) (T11) (A10) (A8) (A10) (A9) (C8) (G8) Frequency
M5 A A A A A A A A A A 0 of 10
M7 A A A A A A A A A A 0 of 10
M9 A A A A A A A A A A 0 of 10
M13 A A A P (t11–12) A A A A A A 1 of 10
M21 A A P (A10–11) A A A A A A A 1 of 10
M25 A A A A A A A A A A 0 of 10
M35 A A A A A A A A A A 0 of 10
tumors with mutation 0 of 7 0 of 7 1 of 7 1 of 7 0 of 7 0 of 7 0 of 7 0 of 7 0 of 7 0 of 7 
Abbreviations: TCF4, transcription factor-4; XRCC2, x-ray repair cross-complementing protein 2; MBD4, methyl-CpG binding domain protein 4; MRE11, meiotic recombination 
11 homolog A; ATR, ataxia telangiectasia and Rad3 related checkpoint kinase 1; MSH3, MutS homolog 3; TGFBR2, transforming growth factor b type II receptor; RAD50, 
RAD50 homolog; MSH6, MutS homolog 6; BAX, BCL2-associated X protein; A, absent; P, present.
Fig. 3. Microsatellite instability target gene mutations: fragment 
analysis of methyl-CpG binding domain protein 4 (MBD4) and 
meiotic recombination 11 homolog A (MRE11) for normal DNA 
from a healthy person, and mutated fragments by insertion of one 
nucleotide in MRe11 in case M13 and in MBD4 in case M21.
medulloblastomas, one with MSI-H and one with MSI-L. 
Overall, among the 10 candidate target genes studied, this 
represents 20% of genes mutated. This rate of mutation 
in candidate target genes, although smaller than what is 
regularly stated for CRC, is comparable to frequencies 
reported for other tumor entities such as pancreatic ductal 
adenocarcinomas, which presents 25% mutated genes,44 
and it is higher than the incidence reported in other stud-
ies,45 indicating that different tumors can present muta-
tions in different targets for instability.46,47 In addition, 
as mentioned above, mutations in candidate target genes 
were mainly reported only in MSI-H tumors, in different 
tumor entities.44,48 Among these different cancers, MSI-L 
malignancies generally do not present mutations in the 
candidate target genes frequently mutated in MSI-H 
tumors, but our results raise the question of whether this 
is true for all MSI-L tumors.
MBD4 is a member of the methyl-CpG binding pro-
tein family, which possesses a methyl-CpG binding 
domain (MBD) and a glycosylase repair domain, repair-
ing mismatched G-T residues at methylated CpG sites.49 
Previous studies in colorectal, endometrial, and gastric 
tumors reported that truncating mutations of MBD4, 
due to the deletion of one nucleotide in the A10 tract of 
exon 3, result in proteins without the glycosylase repair 
domain and therefore with defective glycosylase activ-
ity.49–51 In addition, MBD4 truncated protein had the 
capacity to compete with wild-type protein in a domi-
nant negative manner, causing the accumulation of errors 
in the DNA.51 In our study we observed not a deletion 
but a nucleotide insertion at the A10 tract of the MBD4 
gene. Similar to deletion, insertion of a nucleotide in the 
A10 microsatellite region is also suggested to result in a 
truncated and defective protein.50
MRE11 is a member of the MRE11/NBS1/RAD50 
(MNR) complex, which is essential for the mainte-
nance of DNA integrity. This complex plays a central 
role in recognizing and repairing double-strand breaks 
through homologous recombination or nonhomologous 
end-joining repair pathways. It was previously suggested 
that homo- or heterozygous deletions in the poly(T)11 
within MRE11 intron 4 cause aberrant splicing, with 
skipping of exon 5, leading to a premature stop codon 
and generation of a truncated protein.52 In this study, 
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ize our samples and to determine if CTNNB1 could be 
related to MSI status in medulloblastomas, we searched 
for mutations in its hotspot region but found no evi-
dence. Although no BRAF or CTNNB1 mutations were 
found in the hotspot region screens in these medullo-
blastomas, we cannot exclude the potential existence of 
mutations in other regions of the genes.
In conclusion, this study is the most comprehensive 
analysis of MSI in medulloblastomas to date. We found 
a total of four cases (11%) with instability, three with 
MSI-L, and one with MSI-H, two of which presented 
mutations in MBD4 and MRE11 MSI target genes, 
which have never before been reported in medulloblas-
tomas. While further studies analyzing a larger series 
of both pediatric and adult medulloblastomas are war-
ranted to assess the frequency of MSI, the present work 
suggests the existence of a potential novel molecular 
pathway in a fraction of medulloblastomas associated 
with the presence of MSI.
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we observed a heterozygous insertion in MRE11 T11 in 
case M13. This allele expansion was also identified in a 
CRC tumor sample of a Lynch syndrome patient, and 
can also result in aberrant splicing signals and prema-
ture stop codons of MRE11.52 Nevertheless, the exact 
functional role of the poly(T)11–12 MRE11 mutation is 
not clear, and the same mutation was also reported in a 
lymphoma cell line.53
Although the majority of medulloblastomas occur 
sporadically, they can occur associated with Turcot syn-
drome type 2,22 and it also has been reported in young 
members of families with Lynch syndrome.54–56 Inter-
estingly, biallelic germline mutations in MSH654,55 or 
MLH156 were described in three different patients that 
developed medulloblastoma. Tumors presenting MSH6 
mutations were also found to lack protein expression,54,55 
whereas in medulloblastoma with MLH1 mutation, 
protein expression was not reported.56 Despite due dili-
gence, it was not possible to obtain the family history of 
the four patients with MSI medulloblastoma to assess 
their potential inherited nature. Therefore, we cannot 
exclude the possibility that these MSI-presenting tumors 
arose in a familial cancer context. Aiming to unravel 
this question, somatic BRAF mutations associated with 
sporadic CRC MSI were screened, and no mutation was 
detected. However, at variance with CRC, BRAF muta-
tions have never been detected in medulloblastomas, 
which thus does not exclude the sporadic nature of our 
MSI-positive medulloblastomas. 
b-Catenin is a key player in the Wingless/Wnt signal 
transduction pathway that is involved in medulloblas-
tomas, and mutations were reported previously in only 
5%–9% of the cases.57,58 Aiming to better character-
Fig. 4. DNA sequencing of the microsatellite instability target genes meiotic recombination 11 homolog A (MRE11; t11) and methyl-CpG 
binding domain protein 4 (MBD4; A10): normal DNA from a healthy person for the MRE11 and MBD4 genes (left) and the mutated cases 
M13 for MRE11 and M21 for MBD4 (right). Arrows indicate the insertion of one nucleotide.
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